Director OrbiMed Advisors sold $3.9M in SION shares, reducing its directly held stake by 3.4% at a price 39.1% above the 90-day low. This is the 10th consecutive sale by this entity, reinforcing a clear exit pattern despite a STRONG BUY analyst consensus.

Where it could go — Our 5-6 conviction sells have a 50% rate of beating SPY at 30d; watch $48.44 as a bull break, $32.26 as a bear support level.

Director Thompson sold $3.9M worth of SION shares, reducing his direct holdings by 3.4% at $44.86, which is 7.4% below the 90-day high. This continues a pattern of consistent director selling with no supporting buyer cluster, though it occurs amid a STRONG BUY analyst consensus.

Where it could go — Our 5-6 conviction sells: 50% beat SPY at 30d; watch $32.26 as the bear break level.

Chief Legal Officer Jennifer Fitzpatrick sold $447K in shares from an option exercise, leaving her pre-existing stake unchanged. This is her fourth sell in ten months and is a routine liquidity event, not a signal of reduced conviction, especially with no other insiders buying.

Where it could go — Our 1-4 conviction officer sells historically beat SPY 59% of the time at 30d; watch $48.44 as the bull break, $32.26 as the bear floor.

Director OrbiMed sold $5.3M worth of SION shares at $45.50, reducing their direct holdings by 4.3% while the stock trades 41% above its 90-day low. This continues a pattern of institutional selling with no other insider buyers, though the STRONG BUY analyst consensus provides some counterbalance.

Where it could go — Our 5-6 conviction sells: 55% beat SPY at 30d (n=154, avg +1.5% vs SPY); watch $48.44 as resistance, $32.26 as support.

Director Peter Thompson sold $5.3M in SION shares, reducing his direct stake by 4.3% at $45.50, which is 6.1% below the 90-day high. This continues his pattern of consistent selling with no other insider buyers, contrasting sharply with the analyst STRONG BUY consensus.

Where it could go — Our 5-6 conviction sell signals: 55% beat SPY at 30d; watch $32.26 as critical support.

Director Orbimed Advisors LLC filed a Form 4 Code S (open-market sale) for $2.2M, reducing its stake by 1.6%. This is the first recorded open-market transaction by this director, with zero prior Code-P buys or Code-S sells on file. The sale at $44.61 occurred 4 days before earnings, with a consensus analyst rating of Strong Buy.

Where it could go — If the bear case holds, the stock may test the 90-day low of $32.56; the thesis is invalidated if the stock holds above the transaction price of $44.61 and the analyst consensus proves accurate.

Director Orbimed Advisors LLC filed a Form 4 Code S (open-market sale) for $2.2M, reducing its stake by 1.6%. This is the first recorded open-market transaction by this director, with zero prior Code-P buys or Code-S sells on file. The sale at $44.61 occurred 4 days before earnings, with a consensus analyst rating of Strong Buy.

Where it could go — If the bear case holds, the stock may test the 90-day low of $32.56; the thesis is invalidated if the stock holds above the transaction price of $44.61 and the analyst consensus proves accurate.

Director Orbimed Advisors LLC filed a Form 4 Code S (open-market sale) for $2.2M, reducing its stake by 1.6%. This is the first recorded open-market transaction by this director, with zero prior Code-P buys or Code-S sells on file. The sale at $44.61 occurred 4 days before earnings, with a consensus analyst rating of Strong Buy.

Where it could go — If the bear case holds, the stock may test the 90-day low of $32.56; the thesis is invalidated if the stock holds above the transaction price of $44.61 and the analyst consensus proves accurate.

Director Peter A. Thompson executed a Code-S open-market sale of 48,546 SION shares at $44.61 on 2026-05-07, reducing his stake by 1.6% and realizing $2.2M in proceeds. This is Thompson's first Form 4 filing on record, with no prior buy or sell history to establish a baseline trading pattern. The sale occurred 4 days before earnings (2026-05-11) with consensus EPS of -$0.52, while analyst consensus remains STRONG BUY (14 of 16 buy ratings); stock was 4% below the 90d high and 37% above the 90d low at transaction time.

Where it could go — If the earnings miss (consensus -$0.52) triggers analyst downgrades, the stock historically breaks below the $35.10 30d low; bull case requires the stock to hold above $44.61 and analyst consensus to remain STRONG BUY post-earnings, invalidating the insider-ahead-of-miss thesis.

Director Peter A. Thompson executed a Code-S open-market sale of 48,546 SION shares at $44.61 on 2026-05-07, reducing his stake by 1.6% and realizing $2.2M in proceeds. This is Thompson's first Form 4 filing on record, with no prior buy or sell history to establish a baseline trading pattern. The sale occurred 4 days before earnings (2026-05-11) with consensus EPS of -$0.52, while analyst consensus remains STRONG BUY (14 of 16 buy ratings); stock was 4% below the 90d high and 37% above the 90d low at transaction time.

Where it could go — If the earnings miss (consensus -$0.52) triggers analyst downgrades, the stock historically breaks below the $35.10 30d low; bull case requires the stock to hold above $44.61 and analyst consensus to remain STRONG BUY post-earnings, invalidating the insider-ahead-of-miss thesis.

Director Peter A. Thompson executed a Code-S open-market sale of 48,546 SION shares at $44.61 on 2026-05-07, reducing his stake by 1.6% and realizing $2.2M in proceeds. This is Thompson's first Form 4 filing on record, with no prior buy or sell history to establish a baseline trading pattern. The sale occurred 4 days before earnings (2026-05-11) with consensus EPS of -$0.52, while analyst consensus remains STRONG BUY (14 of 16 buy ratings); stock was 4% below the 90d high and 37% above the 90d low at transaction time.

Where it could go — If the earnings miss (consensus -$0.52) triggers analyst downgrades, the stock historically breaks below the $35.10 30d low; bull case requires the stock to hold above $44.61 and analyst consensus to remain STRONG BUY post-earnings, invalidating the insider-ahead-of-miss thesis.